RayThera raises $110 million for innovative immunology therapies

On April 4, 2025, RayThera, Inc., a biotechnology company based in San Diego, successfully completed its Series A financing round, raising an impressive total of $110 million. The financing was co-led by prominent investment firms Foresite Capital and OrbiMed Advisors, with participation from TTM Capital as well. The funds raised will be utilized to advance RayThera's lead drug candidates through Phase 1 clinical studies, which is a crucial step in the development of new therapies for immunology. RayThera was co-founded by Qing Dong, Ph.D., and Gene Hung, M.D., and is supported by a highly skilled team with significant experience in the biotech and pharmaceutical industries. This new round of funding marks a critical milestone for the company, enabling them to effectively move forward with their drug development initiatives. Qing Dong expressed gratitude for the strong backing from their investors, highlighting their continued support as instrumental for the company's progress in advancing their therapeutic pipeline. Moreover, the collaboration with Foresite Capital and OrbiMed Advisors is noteworthy, given their history of funding a previous venture, XinThera, which adds a layer of trust and expectation for RayThera's potential. Both Michael Rome, Ph.D., from Foresite Capital, and Carl Gordon, Ph.D., CFA, from OrbiMed, commented on the impressive progress made by RayThera in a relatively short period, signaling confidence in the team's ability to develop first-in-class and best-in-class therapies that address critical unmet medical needs. As the biotechnology sector continues to grow, the successful funding of RayThera should serve as a compelling case for investors in the space. The advancements made from this financing round could lead to significant developments in immunological treatments, benefiting patients and the broader healthcare landscape. The company plans to allocate its new resources wisely to ensure the effective execution of its clinical program, paving the way for potentially life-changing therapies.